Skip to main content

Table 1 Baseline characteristics of trial participants

From: An explanatory randomised controlled trial of a nurse-led, consultation-based intervention to support patients with adherence to taking glucose lowering medication for type 2 diabetes

  Intervention arm Standard Care arm All participants
Socio demographic N=126 N=85 N=211
% male (N) 61.9% (78) 70.6% (60) 65.4% (138)
Age (years) 62.5 (11.0) 64.1 (10.3) 63.2 (10.7)
IMD Deprivation rank (0-100) 10.2 (6.4) 10.4 (6.8) 10.3 (6.8)
Health-related    
SF12 Physical [3] (norm 50 43.3 (11.2) 45.5 (10.3) 44.2 (10.9)
range 0-100)    
SF12 Mental [3] (norm 50 48.0 (10.6) 50.0 (9.6) 48.8 (10.2)
range 0-100)    
Duration of diabetes (years) 6.7 (4.8) 6.9 (5.3) 6.8 (5.0)
Weight (kg) 97.4 (21.7) 94.5 (19.6) 96.2 (20.9)
Systolic blood pressure (mmHg) 137.4 (16.2) 136.2 (15.9) 136.9 (16.0)
Diastolic blood pressure (mmHg) 78.3 (8.9) 78.1 (9.1) 78.2 (9.0)
HbA1c (%) [1] 8.37 (1.25) 8.28 (1.22) 8.33 (1.24)
HbA1c (mmol/mol) 68.0 (2.7 67.0 (2.4) 67.5 (2.6)
Medication-related    
% treated with metformin (N) [4] 86.7% (104) 87.9% (73) 87.2% (177)
Metformin daily dose (mg) * [4] 1450 (795) 1525 (780) 1480 (788)
Total number of medications taken/day 5.7 (2.4) 5.9 (2.6) 5.8 (2.5)
Adherence (MARS) [2] (range 5-25) 23.6 (2.3) 23.6 (2.8) 23.6 (2.5)
  1. Values are mean (SD) unless otherwise stated: missing data: [1] 17; [2] 23; [3] 2; [4] 8.
  2. * for those treated with metformin.
  3. MARS Medication Adherence Report Scale.